arrow
T

Tsutomu Sato

University of Toyama
H指数:49
被引数:9,320

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Antiapoptotic BCL2 family proteins BCL-XL and MCL1 as factors predicting resistance against venetoclax plus azacitidine for patients with newly diagnosed acute myelogenous leukemia

抗凋亡BCL2家族蛋白BCL-XL和MCL1作为预测新诊断急性髓系白血病患者对维奈克拉联合阿扎胞苷耐药性的因素

2026-01-300
PRE
Robotic beyond total mesorectal excision for primary rectal cancer: A comparison of Short-term outcomes with standard total mesorectal excision

机器人辅助手术超越全直肠系膜切除术治疗原发性直肠癌:短期疗效与标准全直肠系膜切除术的比较

2025-12-010
PRE
Inferior versus medial approach in laparoscopic and robotic surgery with complete mesocolic excision for right-sided colon cancer: propensity score-matched analysis

腹腔镜与机器人完全结肠系膜切除右半结肠癌手术中下路与内侧入路的比较:倾向性评分匹配分析

2025-07-300
OAAI
Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies

CD26-Expressing T细胞恶性肿瘤的新型CD26-Targeted嵌合抗原受体T细胞疗法的开发

CELLS
IF5.2
2023-08-145
OAAI
DPP8 Selective Inhibitor Tominostat as a Novel and Broad-Spectrum Anticancer Agent against Hematological Malignancies

DPP8选择性抑制剂Tominostat作为抗血液系统恶性肿瘤的新型广谱抗癌剂

CELLS
IF5.2
2023-04-063
OAAI
Possible clinical outcomes using early enteral nutrition in individuals with allogeneic hematopoietic stem cell transplantation: A single-center retrospective study

早期肠内营养对异基因造血干细胞移植患者可能的临床结局: 一项单中心回顾性研究

2021-03-019
PREAI
Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial
2020-03-0172
PREAI